New Tool for Predicting the Outcome of Pediatric Brain Tumor

Biomarker that will aid in predicting the prognosis of pediatric ependymomas has been identified.

Highlights

The current prognostic markers used in ependymomas are poor indicators of its outcome.
New research has identified the epigenetic mechanism behind ependymomas.
Those tumors that exhibited a loss of histone H3K27me3, were more aggressive.

A simple and inexpensive tool for assessing the prognosis of pediatric brain tumors called ependymomas, has been identified.

The study, by a multi-institutional group of researchers, led by investigators at Children's Hospital Los Angeles and the University of Michigan, demonstrates the epigenetic mechanism behind these tumors.

Novel Laser Imaging Technique Identifies Brain Tumors Among Healthy Tissue
New laser technique enables the tumor to be easily distinguished from normal tissue and this is possible due to the signals emitted by tissue with different cellular structures.

‘Detecting the presence of histone H3K27me3, is an effective tool to determine the accurate prognosis and identify ependymoma patients who would benefit from epigenetic therapies.’

This may offer future opportunities for novel therapeutic options. It will be published online by Science Translational Medicine on November 23.

Ependymomas

Ependymomas arise from the ependymal cells that line the ventricles of the brain and the center of the spinal cord. They are soft, grayish or red tumors that may contain cysts or mineral calcifications.

High Response Rate in Phase I/II Trial of Pediatric Brain Cancer
A high response rate with a single drug in a phase I/II trial of pediatric glioma has set the stage for combination therapy with higher response and lower toxicity.

Symptoms of an ependymoma are related to the location and size of the tumor. In babies, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows.

In older children and adults, nausea, vomiting, and headache are the most common symptoms.

Genetic Mutation of Aggressive Brain Tumor Identified
Genetic mutations found in brain tumors help distinguish aggressive meningiomas from benign forms and help design better trials and more precise treatment approaches.

Ependymomas are relatively rare tumors in adults, accounting for 2-3% of primary brain tumors.

They are the sixth most common brain tumor in children. About 30% of pediatric ependymomas are diagnosed in children younger than 3 years of age.

Glioma Brain Tumor
Democrat Senator Edward Kennedy has been diagnosed with Glioma, a kind of brain tumor. Tests carried out on the 76 -year old politician revealed a tumor on his left parietal lobe.

Childhood posterior fossa ependymomas (PF) are tumors found largely in the hind brain (consisting of the cerebellum, pons and the brainstem) of children.

Routine assessment of tumor grade and other markers in PF ependymomas are poor indicators of the outcomes in these tumors. This marks the need for new prognostic markers.

Genomic sequencing efforts have failed to identify mutations in these tumors, and the origin of PF ependymomas remains obscure.

Though these tumor cells lack recurrent genetic mutations, a subset of these tumors exhibit alterations in DNA methylation.

In this study, the researchers looked at modification of histones which are the protein components of the chromatin around which DNA winds, and which play a role in gene regulation. In particular, they looked at histone H3.

Co-lead investigator, Sriram Venneti, MD, PhD, of the Department of Pathology at the University of Michigan, observed that histone H3 is modified differently in pediatric posterior fossa ependymoma.

Specifically, 80% of these tumors exhibited loss of the H3K27me3 a repressive mark, while 20% of tumors retained H3K27me3.

Researchers then examined the MRIs and outcomes of children treated for these tumors and identified that tumors with loss of H3K27me3 tumors behaved more aggressively and showed poor overall survival.

This suggests that reduced H3K27me3 may be a prognostic indicator in PF ependymomas.

"Detection of H3K27me3 by immunohistochemical staining is a widely available and cost effective surrogate molecular marker. This test can be readily implemented in most departments of pathology and provides a much-needed tool to risk stratify and identify ependymoma patients who would potentially benefit from epigenetic therapies," said co-lead investigator Alexander R. Judkins, MD, of the Department of Pathology and Laboratory Medicine at CHLA and Keck School of Medicine of the University of Southern California.

This loss in H3K27me3, along with other epigenetic changes, was similar to that observed in another type of pediatric brain tumor of the hind brain region termed diffuse intrinsic pontine gliomas (DIPGs). This suggests that both of these tumors arise from similar epigenetic states.

The researchers found that that low methylation of H3K27me3 is important to the development of tumors in this region of the brain.

According to the Collaborative Ependymoma Research Network (CERN) Foundation, the current standard therapy for ependymomas includes total surgery that may be followed by radiation therapy.

Complete surgical resection is often not possible due to tumor location and concerns about damaging the surrounding brain during surgery.

Such treatment can affect the cognitive functions especially to pediatric patients.

By demonstrating the epigenetic mechanism, researchers will be better able to identify these tumors, determine a more accurate prognosis and importantly develop better therapeutic options.

References

Ependymoma - (http://www.abta.org/brain-tumor-information/types-of-tumors/ependymoma.html?referrer=https://www.google.co.in/)

Source-Medindia